Trial Title:
Monitoring of Chronic Conditions in Breast Cancer
NCT ID:
NCT05587777
Condition:
Breast Cancer
Chronic Fatigue Syndrome
Conditions: Official terms:
Breast Neoplasms
Fatigue Syndrome, Chronic
Fatigue
Chronic Disease
Conditions: Keywords:
fatigue
breast cancer
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
REBECCA-1 is an observational study. Clinical research is undergoing a revolutionary
change. The use of electronic patient records (EHR), digital registers, smartphones etc
will create "real-world data" (RWD) that provides great opportunities for advancing
clinical research, but so far this opportunity has been little exploited. The REBECCA -1
study will observe and monitor fatigue in breast cancer survivors. Investigators will use
self reported questionnaires (PROM-data), blood tests and objective regulations like the
REBECCCA -1 smart watch that will register amount of steps every day, leaving the house,
visiting friends, cafes etc. There will be three observational arms; 1.high fatigue, 2.
low fatigue and 3. a healthy control arm. After the patients have finished their
treatment, they will receive the REBECCA smart watch, a REBECCA app on the smart phone
and a REBECCA plus device on their computer, The next offend are also invited to report
their evaluation through the same apps. The observational time will be 1 year and
comparison between the subjective PROM data , the objective REBECCA watch and the
biological samples will be obtained.
Detailed description:
Detailed Description:
1. Background:
Clinical research is undergoing revolutionary changes by use of electronic patient
records (EHR), digital registers and smartphones. The widespread use of portable
devices have led to possibilities to collect "real-world data" (RWD) that provides
great opportunities for advancing clinical research.
Fatigue or exhaustion is one of the most common and most annoying late side effects
after breast cancer treatment. Cancer Related Fatigue (CRF) may be elevated even
before starting treatment and generally increases in intensity during treatment . It
can also persist for years after completion of treatment in otherwise healthy cancer
survivors and studies suggest that up to a third experience persistent fatigue for
up to 10 years after being diagnosed with cancer. CRF is multi-dimensional and can
have physical, mental and emotional manifestations, including general weakness,
decreased concentration or attention, decreased motivation or interest in
participating in regular activities, as well as emotional lability. Fatigue has also
been shown to have a negative impact on work, social relationships, mood and daily
activities and causes a significant reduction in overall quality of life during and
after treatment for the patients affected. Thus, studying of RWD in CRF will be an
appropriate method and design. As far as known this has not been done before.
The biological mechanisms associated with the development of CRF may involve
inflammatory processes contribute to fatigue during and especially after cancer
treatment. Various cytokines may be produced during cancer treatment in response to
tissue damage from radiation or chemotherapy. Inflammatory candidate biomarkers
include Interleukin (IL) 1b, IL6, IL10, IL-17, IL1βRa and IL1-RII 32, 33. Heat shock
Protein (HSP) 90 is another current biomarker candidate as it has been shown to
reflect the severity of fatigue in patients with Crohn's disease.
2. Rationale behind the REBECCA project
By using multi-source RWD in clinical studies, it will be possible to monitor the
quality of life of patients and have a unique opportunity to map the challenges
patients have in their daily lives in terms of work life participation, physical
activity, social activity / relationships and their concerns. At the same time, the
investigators will explore whether different immunological candidate biomarkers can
provide prognostic information related to the development of fatigue in this patient
group.
3. Objectives
REBECCA-1 is an observational study in which a REBECCA smartwatch will be used to
monitor the quality of life and fatigue in breast cancer patients
4. Spesific aims include:
- Evaluating whether the use of REBECCA-collected patient information (i.e.
collection of continuous RWDs and PROMs) will provide better insight into
fatigue in breast cancer survivors.
- Evaluating immunological biomarkers such as HSP90, IL1b, IL6, IL10, IL-17,
IL1βRa, IL1-RII, HPX, CFB, APOA4 and Serpin-F1 and DNA methylation patterns.
5. Study design
The REBECCA-1 sub-study: Characterize the quality of life and late effects in breast
cancer patients.
In REBECCA-1, participants will be included in 3 groups à n = 49 Two of the groups
include breast cancer patients. After treatment, the patient will be assigned to one
of the two study arms as described below. The third arm is a control group
consisting of healthy women between 19 and 70 years.
After undergoing treatment (surgery, chemotherapy given neoadjuvant or adjuvant and
radiation), the breast cancer patients will again fill in PROM data and submit
biological material and be assigned to the "CRF arm" and "Mild CRF arm",
respectively.
"Cancer Related Fatigue (CRF) arm" n = 49: The participants who after evaluation of
the form VAS-fatigue have a change of f-VAS> 25mm from the time of inclusion to
evaluation after completion of treatment and / or fVAS score> = 50 mm are stratified
into the group "CRF arm".
"Mild Cancer Related Fatigue (mild CRF) arm" n = 49: Patients with a final fVAS
score <50mm is randomized to the group "Mild CRF arm".
All participants will be able to borrow a smartwatch during the observation period,
which they must wear for 12 months (i.e. from month 6 to month 18). In addition, the
participants must install a REBECCA patient app on their mobile and a plug-in on
their PC in order to obtain objective RWD related to the participants' quality of
life and lifestyle over the next 12 months. The data collected by means of these
devices is described in the figure which shows which data is collected via the
smartwatch and the mobile phone
At all time points i.e. at diagnosis, 6, 12 and 18 months after the time of
inclusion, patient reported outcome measures (PROMs), medicine list, biological
samples and RWD from the smart watch system on REBECCA platform from all the
participants in all three subgroups.
6. REAL WORLD DATA COLLECTION
A. Smartwatch:
Acceleration, pulse, Activity sessions (type of exercise (running, walking, walking,
cycling Length of activity(minutes, training distance (km) and altitude meters
Intensity level(number of calories, intensity B. Smartphone and mobile apps
- GPS positions (movement pattern)
- Answer to questionnaires
- Photo initiated in the Rebecca app (related to meals/eating habits and
environment)
- Publicity available data from map services location and environmental. C.
REBECCA. PC plug in internet from *Social media such as Facebook, You Tube
etc., D. REBECCA companion app (optional) *answer questions about the patient's
quality of life , symptoms and environment
7. Patient Reported Outcome Measures (PROMs)
Patient-reported data (PROMs) related to lifestyle, quality of life, working
conditions, sleep and medication use will also be collected in REBECCA. For this
purpose, the investigators will both use standardized PROM forms (ΕORTC-QLQ-BR2340,
SF-3641, ΕORTC-QLQ-C3042, HAD43, FSS44, FQ45 og VAS-fatigue34, 46, 47) and
self-report form.
8. Collection and analyses of blod-, urine- and faeces samples
All patients included in the REBECCA-1 sub-study will be asked to give blood, urine
and faeces samples i.) at the time of diagnosis ii.) after the end of treatment
(month 6) and iii.) at 12 and 18 months follow-up. A tissue sample will also be
taken at the time of diagnosis. The blood samples will be used to investigate
whether immunological biomarkers such as HSP90, IL1b, IL6, IL10, IL-17, IL1βRa,
IL1-RII, HPX, CFB, APOA4 and Serpin-F1-can provide prognostic information related to
the development of fatigue in breast cancer patients.
DNA methylation will be examined by Full-genome methylation assays using Illumina's
Human Methylation 850K platform and 8 CpG sites from our partner Mylin Torres will
in addition be validated.
9. Data flow
The REBECCA system will function as a data collection system, and will be a "stand
alone" system that will have no communication with other systems in the hospital.
i.) A smartwatch: The smartwatch to be used in REBECCA for RWD collection will be a
commercial Garmin-type smartwatch.
ii.) REBECCAs patient app (pApp): GPS data, data from third-party health apps,
images and sensor data will first be uploaded to REBECCA's pApp. The data will be
stored in the app on a separate memory location on the phone, which is isolated and
therefore not available for the other phone apps. .
iii.) REBECCAs PC plug-in: patients will install this on their PC. They will be
given a description of how to do this. The connection between the patient ID and
REBECCA's browser plug-in will also take place here via a unique code, generated in
the pApp on the mobile, which the patient enters into the browser. The user ID is
stored so that the patient does not have to log in every time they reopen the
browser. The REBECCA's PC plug-in utilizes the browser's local storage space to
store information that is critical to its functionality, while the data from the
patient's online activity is directly transferred and stored on the REBECCA server
for subsequent processing.
iv.) REBECCAs companion app (cApp): Family members or close friends who will
contribute information to REBECCA will report this data in REBECCA's companion app,
which they will install on their mobile. .
v.) RedCap server at HelseVest IKT: Deidentified clinical data and PROM data will be
stored in the RedCap server at HelseVest IKT before being transferred pseudonymously
and encrypted to the remotely managed REBECCA server.
10. Data storage, privacy and data security
Data security and privacy are a high priority in REBECCA and will of course be in
line with both Norwegian and European laws. The law firm TimeLex, located in
Belgium, is responsible for creating an operational data security and ethical
framework that the study will follow. This means that all precautions will be taken
in REBECCA to respect the privacy of study participants in accordance with European
Parliament and Council Regulation (EU) 2016/679 of 27 April 2016 regarding the
protection of individuals with regard to the processing of personal data and the
free movement of such data , and repealing Directive 95/46 / EC (General Data
Protection Regulation) (GDPR))50. TimeLex, will identify and describe the ethical
guidelines that apply to the various REBECCA participating countries, and the list
of necessary measures will apply to the entire ethical operation of the REBECCA
project.
11. Expected impact of the REBECCA project
REBECCA aims to use "real-world data" combined with an advanced data management platform
and innovative methods for modeling causal data, to close the gap between clinical
research and clinical practice in the treatment of cancer patients. The REBECCA project
will initially focus on breast cancer, but will also demonstrate the REBECCA system's
transmission to other cancers such as prostate cancer. REBECCA's technological and
methodological advances will also be relevant for other clinical research domains that
want to investigate the causal relationship between several clinical factors (lifestyle
and environmental factors, and comorbidities), through analysis of registry and biobank
data and observational data from patients' real life / everyday life.
12 Among REBECCAs milestones are:
A. Development of new approaches to measurement, and a better understanding, of
indicators related to the patient's health status and quality of life.
B. Development of methods for statistical and causal analysis of "real-world data".
C. Clinical studies in cancer-related fatigue / fagitue, cancer-induced peripheral
neuropathy and cancer-related osteoporosis.
D. Examination of patient monitoring in clinical trials, as a tool to improve the quality
of life of cancer patients.
E. Generation and reuse of data sets that will enable the investigation of new medical
issues as well as the design, implementation and delivery of an AI-enhanced data
collection and management system for comprehensive monitoring of breast cancer survivors'
health status and quality of life.
F. To offer new tools and data to clinicians that lead to improved follow-up of cancer
patients.
G. Improved patient experience and quality of life due to detailed monitoring and a more
personal follow-up.
Digital health (eHealth) has come more into focus during the COVID-19 pandemic. The
REBECCA system will be able to contribute to development, increased use and increased
competence in eHealth at Stavanger University Hospital by offering digital data
collection, digital solutions for patient monitoring, digital solutions for early
detection of comorbidities, use of artificial intelligence models as analysis tools,
better utilization of health data from health registers and research biobanks as well as
offering health care in new ways etc.
Criteria for eligibility:
Study pop:
All breast cancer patients who have undergone surgery at SUS, and who meet the inclusion
criteria, will be informed about the REBECCA-1 sub-study and written electronic consent
will be obtained from those who wish to participate. All potential participants will be
women due to the nature of breast cancer.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Breast cancer patients with histologically detectable M0 breast cancer (stage 0-III)
who require neoadjuvant or adjuvant endocrine, chemo and / or radiation therapy at
least and no more than 3 months before initiation of study.
- Female breast cancer patients between 19 and 80 years of age.
- Patients who have increased their life expectancy beyond the first 3 months after
starting treatment.
- Patients who have the ability to understand the protocol and can participate in the
follow-up plan.
- Patients who have an absence of psychological, familial, sociological or
geographical condition that potentially impedes compliance with the study protocol
and follow-up plan.
Exclusion criteria:
- Male breast cancer patients.
- Patients who do not agree to the study protocol.
- Patients with a previous cancer diagnosis (excluding skin cancer treated only by
surgery).
- Patients who have previously been treated with some form of chemotherapy / radiation
therapy.
Gender:
Female
Gender based:
Yes
Gender description:
Breast Cancer affects women in 99% of all cases
Minimum age:
19 Years
Maximum age:
80 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Helse Stavanger HF
Address:
City:
Stavanger
Zip:
4068
Country:
Norway
Status:
Recruiting
Contact:
Last name:
Tone Hoel Lende, PhD
Phone:
47861295
Email:
leth@sus.no
Contact backup:
Last name:
Håvard Søiland, PhD
Phone:
45636028
Email:
hsoiland@gmail.com
Start date:
June 15, 2022
Completion date:
June 15, 2028
Lead sponsor:
Agency:
Helse Stavanger HF
Agency class:
Other
Source:
Helse Stavanger HF
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05587777
